stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) EPS (diluted)
Arcus Biosciences, Inc.'s EPS (diluted) for fiscal 2025 was −$3.29, compared with −$3.14 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.63. Over the past ten years it has ranged from −$29.04 (fiscal 2017) to $0.71 (fiscal 2021); the current reading is higher than 50% of that period. Arcus Biosciences, Inc. ranks 405th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.29 | — |
| FY2024 | −$3.14 | — |
| FY2023 | −$4.15 | — |
| FY2022 | −$3.71 | — |
| FY2021 | $0.71 | — |
| FY2020 | −$2.24 | — |
| FY2019 | −$1.93 | — |
| FY2018 | −$1.43 | — |
| FY2017 | −$29.04 | — |
| FY2016 | −$20.80 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.00 | — |
| Jun 2026 | −$0.72 | — |
| Mar 2026 | −$1.02 | — |
| Dec 2025 | −$0.89 | — |
| 35 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| BEAM Beam Therapeutics Inc. compare | −$1.04 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$1.71 |
| XNCR Xencor, Inc. compare | −$2.17 |
| MBX MBX Biosciences, Inc. compare | −$2.41 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| RCUS Arcus Biosciences, Inc. | −$3.63 |
| IDYA IDEAYA Biosciences, Inc. compare | −$4.49 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RCUS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement